

**Supplementary Table SIII** Sensitivity analysis for mortality in patients that received controlled ovarian stimulation before starting anticancer treatments.

Study excluded	Random effect			<i>I</i> -squared (%)	<i>I</i> -squared <i>P</i> -value
	RR	95% CI	<i>P</i> -value		
<a href="#">Muñoz et al. (2019)</a>	0.54	0.38–0.76	0.001	0.0	0.609
<a href="#">Marklund et al. (2020)</a>	0.69	0.35–1.34	0.275	0.0	0.878
<a href="#">Greer et al. (2021)</a>	0.50	0.34–0.73	<0.001	0.0	0.986
<a href="#">Moravek et al. (2021)</a>	0.54	0.38–0.77	0.001	0.0	0.609

*I*-squared, Higgins index; RR, relative risk.